

FLAB

DECLARACIONES DE REDUCCIÓN DE RIESGO DE ENFERMEDAD DEL ARTÍCULO 14 DEL REGLAMENTO 1924/2006 – Estado de tramitación

RELACIÓN SALUD	SOLICITANTE	REFERENCIA EFSA	RESULTADO EVALUACION EFSA	REGLAMENTO COMISIÓN	OBSERVACIONES
Plant stanol esters and blood cholesterol	<i>NcNeil Nutritionals Ltd</i>	EFSA-Q-2008-118	<u>Positive</u> Proposal of wording: “Plant stanol esters has been shown to lower/reduce blood cholesterol. Blood cholesterol lowering may reduce the risk of heart coronary disease”	Reglamento 983/2009 ¹	Autorización alegación: “Se ha demostrado que los ésteres de fitoestanol disminuyen/reducen la colesterolemia. Una tasa elevada de colesterol constituye un factor de riesgo en el desarrollo de cardiopatías coronarias”
Evolus® and reduce arterial stiffness	<i>Valio Limited</i>	EFSA-Q-2008-218	<u>Negative</u> Cause and effect relationship has not been established	Reglamento 983/2009	Denegación alegación
Plant sterols and blood cholesterol	<i>Unilever PCL (UK) y Unilever N.V (Holanda)</i>	EFSA-Q-2008-085	<u>Positive</u> Proposal of wording: “Plant sterols has been shown to lower/reduce blood cholesterol. Blood cholesterol lowering may reduce the risk of	Reglamento 983/2009	Autorización alegación: “Se ha demostrada que los fitoesteroles disminuyen/reducen la colesterolemia. Una tasa elevada de colesterol constituye un factor de riesgo en el desarrollo de cardiopatías coronarias”

¹ Reglamento (CE) n° 983/2009 de la Comisión de 21 de Octubre de 2009 sobre la autorización o la denegación de determinadas declaraciones de propiedades saludables en los alimentos relativas a la reducción del riesgo de enfermedad y las relativas al desarrollo y la salud de los niños (DO L 277 de 21.10.2009)

			<i>heart coronary disease”</i>		
Femarelle® and bone mineral density	<i>Se-Cure Pharmaceuticals Ltd</i>	EFSA-Q-2008-078	Negative <i>Cause and effect relationship has not been established</i>	Pendiente	
Neopuntia® and blood lipid parameters	<i>BIO SERAE</i>	EFSA-Q-2008-214	Negative <i>Cause and effect relationship has not been established</i>	Reglamento 983/2009	Denegación autorización
Ocean Spray Cranberry Products ® and urinary tract infection in women	<i>Ocean Spray International Services Limited UK</i>	EFSA-Q-2008-117	Negative <i>Cause and effect relationship has not been established</i>	Pendiente	
Melgaco mineral water and reduction of glycaemia	<i>Unicer Bebidas de Portugal SGPS, SA</i>	EFSA-Q-2008-219	Negative <i>Cause and effect relationship has not been established</i>	Pendiente	
Bimuno™ and support of the immune system	<i>Clasado Limited</i>	EFSA-Q-2009-00230	Negative Cause and relationship has not been established	Pendiente	
Bimuno™ and reduction of the bad bacteria that can cause travellers’ diarrhoea	<i>Clasado Limited</i>	EFSA-Q-2009-00232	Negative Cause and relationship has not been established	Pendiente	
OPC Premium™ and the reduction of blood cholesterol	<i>GP International Holding B,V</i>	EFSA-Q-2009-00454	Negative Cause and relationship has not been established	Pendiente	
Calcium+Vitamin D3 chewing tablets and bone loss	<i>Abtei Pharma Vertriebs GmbH</i>	EFSA-Q-2009-721	Negative Cause and relationship has not been established	Pendiente	
Lycopeno- whey complex (bioavailable lycopene) and risk of	<i>Cambrigde Theranostics Ltd.</i>	EFSA-Q-2009-703	Negative Cause and relationship has not been established	Pendiente	

atherosclerotic plaques					
Danacol® and blood cholesterol	<i>Danone France</i>	EFSA-Q-2009-779	<u>Positive</u> Proposal of wording: <i>“Phytosterols have been shown to lower/reduce blood cholesterol. High blood cholesterol is a risk factor in the development of coronary heart disease”</i>	Pendiente	
OPC Premium™ and the reduction of blood cholesterol	<i>GP International Holding B.V</i>	EFSA-Q-2009-00454	<u>Negative</u> Cause and relationship has not been established	Pendiente	
Glucosamine hydrochloride and reduced rate of cartilage degeneration and reduced risk of development of osteoarthritis	<i>GP International Holding B.V</i>	EFSA-Q-2009-00412	<u>Negative</u> Cause and relationship has not been established	Pendiente	

Elaboración: *FIAB*. En caso de aplicación, la empresa debe remitirse a la normativa e informe citados.

Fuente: *EFSA* y *Comisión Europea*

Última actualización: *Noviembre de 2009*